Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P37059
UPID:
DHB2_HUMAN
Alternative names:
20 alpha-hydroxysteroid dehydrogenase; E2DH; Estradiol 17-beta-dehydrogenase 2; Microsomal 17-beta-hydroxysteroid dehydrogenase; Short chain dehydrogenase/reductase family 9C member 2; Testosterone 17-beta-dehydrogenase
Alternative UPACC:
P37059; B2R7T4
Background:
17-beta-hydroxysteroid dehydrogenase type 2 (17β-HSD2) plays a pivotal role in steroid metabolism, catalyzing the NAD-dependent oxidation of potent 17beta-hydroxysteroids like estradiol, testosterone, and dihydrotestosterone into their less active forms. This enzymatic activity is crucial for regulating the biological potency of these steroids, impacting various physiological processes.
Therapeutic significance:
Understanding the role of 17-beta-hydroxysteroid dehydrogenase type 2 could open doors to potential therapeutic strategies. Its involvement in the metabolism of key sex steroids suggests its potential impact on diseases related to steroid hormone imbalance.